In vitro and in vivo assessment of the antibacterial activity of colistin alone and/or in combination with other antibiotics against A. baumannii and E. coli.
Limited therapeutic options are available for treating severe infections caused by multidrug-resistant (MDR) and extensively drug-resistant (XDR) gram-negative pathogens. We investigated the activities of colistin (COL) as a monotherapy and combined with antimicrobials against Acinetobacter baumannii in vitro and evaluated the efficacy of intravenous colistimethate sodium (CMS) in a murine model of urinary tract infection (UTI) induced by MDR Escherichia coli. Minimum inhibitory concentration, Monte Carlo simulation, fractional inhibitory concentration index, time-kill study and erythrocyte lysis assay were applied to evaluate the effect and cytotoxicity of COL, meropenem (MER), imipenem (IMP), doripenem (DOR) and sulbactam (SUL) alone or in combination. For in vivo experiment, bacterial burden determination and histopathological examination were performed to evaluate the efficacy of CMS against UTI. 98.12% of A. baumannii was susceptible to COL. In a checkboard assay, COL combined with DOR showed the highest rate of synergism (60%). No antagonism or cytotoxicity was observed. All COL-based combinations were able to inhibit or slow bacterial re-growth in a time-kill assay. In an in vivo activity study, intravenous CMS reduced not only the bacterial load but also inflammation and maintained structural integrity of the infected bladders and kidneys. The effectiveness of COL alone in vitro and in vivo suggested that intravenous CMS will be an effective and available therapeutic strategy for UTI due to MDR gram-negative pathogens. In-depth in vitro tests demonstrated that COL combined with DOR could be an attractive option, especially when COL MIC of the pathogen is ≥ 1 μg/ml.